Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer

不可逆电穿孔与免疫疗法相结合用于胰腺癌的全身治疗

基本信息

  • 批准号:
    10737800
  • 负责人:
  • 金额:
    $ 14.27万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-01-20 至 2025-12-31
  • 项目状态:
    未结题

项目摘要

Abstract The goal of cancer immunotherapy is to utilize the patient’s immune system to reject the invading “foreign” tumor. However, the pancreatic cancer microenvironment is characterized by an abundance of immunosuppressive cells and a dense stroma that prevents infiltration of anti-tumor immune cells. Electroporation is a technique that has been utilized for decades in the laboratory; electrical voltage is applied to cells to make holes for delivery of DNA and RNA. Irreversible electroporation (IRE) is a technique now being used clinically for ablation of localized tumors that cannot be removed surgically (locally advanced tumors). Our objective is to use IRE as an "in situ vaccine" to help the host recognize foreign tumor proteins (neoantigens) and generate anti-tumor immune responses that will decrease recurrence rates. We have utilized mouse models of pancreatic cancer to show that IRE generates anti-tumor immune cells that prevent growth of new tumors (prophylactic immunity). We hypothesize that combining IRE with agents that augment the immune response will result in inhibition of established, distant tumors (therapeutic immunity or “abscopal” effects). In Aim 1, we will use mouse models to compare the effects of IRE to radiation therapy (XRT), as this is the most relevant clinical comparator. Both methods are used clinically for the ablation (killing) of locally advanced pancreatic cancer but have been shown stimulate systemic immune responses in preclinical models. We hypothesize that IRE will induce stronger immune responses because XRT causes fibrosis (scarring) that will inhibit immune cell infiltration. In Aim 2, we will combine local ablation with local delivery of agents that stimulate the innate immune system in mouse models of metastatic pancreatic cancer. In Aim 3, we will use a novel model in which human tumors and their associated immune cells are implanted into immunocompromised mice in order to create a “humanized” immune system. We will use this model to study the effects of IRE on human tumors. We have assembled a multi-disciplinary team that encompasses broad expertise in IRE, mouse tumor models, stromal biology, immunotherapy, clinical trials, and clinical care of patients with pancreatic cancer. We envision that the combination of IRE with immunotherapy will be first beneficial to patients with locally advanced pancreatic cancer. However, if effective, this approach may also be beneficial to patients with metastatic disease. Since the IRE technique is already in use clinically, a clinical trial in which one or more of the agents to be studied is delivered during or after IRE as adjuvant therapy would likely be feasible in the near future. We will use data from the proposed research to design such a study.
摘要 癌症免疫治疗的目标是利用患者的免疫系统来拒绝入侵的“外来” 肿瘤然而,胰腺癌微环境的特征是大量的 免疫抑制细胞和致密的基质,防止抗肿瘤免疫细胞的浸润。 电穿孔是一种已经在实验室中使用了几十年的技术;施加电压, 让细胞产生孔洞来输送DNA和RNA。不可逆电穿孔(IRE)是目前研究较多的一种技术 临床上用于消融不能手术切除的局部肿瘤(局部晚期 肿瘤)。我们的目标是将IRE作为一种“原位疫苗”,帮助宿主识别外源肿瘤蛋白 (新抗原)并产生抗肿瘤免疫应答,这将降低复发率。我们有 利用胰腺癌小鼠模型显示,IRE产生抗肿瘤免疫细胞, 新肿瘤的生长(预防性免疫)。我们假设IRE与能够增强 免疫应答将导致对已建立的远处肿瘤的抑制(治疗性免疫或 “远位”效应)。在目标1中,我们将使用小鼠模型来比较IRE与放射治疗的效果 (XRT),因为这是最相关的临床对照药物。这两种方法在临床上都用于消融 (杀死)局部晚期胰腺癌,但已显示刺激全身免疫反应, 临床前模型。我们假设IRE将诱导更强的免疫应答,因为XRT会引起 纤维化(疤痕),这将抑制免疫细胞浸润。在目标2中,我们将联合收割机局部消融与 在转移性胰腺癌的小鼠模型中递送刺激先天免疫系统的药剂。 在目标3中,我们将使用一种新的模型,其中植入了人类肿瘤及其相关的免疫细胞 植入免疫缺陷小鼠体内,以创造一个“人源化”的免疫系统。我们将利用这一模式, 研究IRE对人类肿瘤的影响。我们组建了一个多学科团队, 在IRE、小鼠肿瘤模型、基质生物学、免疫治疗、临床试验和临床护理方面的广泛专业知识 胰腺癌的患者。我们设想IRE与免疫疗法的结合将是第一个 对局部晚期胰腺癌患者有益。然而,如果有效,这种方法还可以 对转移性疾病患者有益。由于IRE技术已经在临床上使用, 在IRE期间或之后给予一种或多种待研究药物作为辅助治疗的临床试验 在不久的将来,这种疗法可能是可行的。我们将使用拟议研究中的数据来设计 这样的研究。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rebekah White其他文献

Rebekah White的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rebekah White', 18)}}的其他基金

Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer
不可逆电穿孔与免疫疗法相结合用于胰腺癌的全身治疗
  • 批准号:
    10331072
  • 财政年份:
    2021
  • 资助金额:
    $ 14.27万
  • 项目类别:
Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer
不可逆电穿孔与免疫疗法相结合用于胰腺癌的全身治疗
  • 批准号:
    10599014
  • 财政年份:
    2021
  • 资助金额:
    $ 14.27万
  • 项目类别:
Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer
不可逆电穿孔与免疫疗法相结合用于胰腺癌的全身治疗
  • 批准号:
    10154535
  • 财政年份:
    2021
  • 资助金额:
    $ 14.27万
  • 项目类别:
Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer
不可逆电穿孔与免疫疗法相结合用于胰腺癌的全身治疗
  • 批准号:
    10577802
  • 财政年份:
    2021
  • 资助金额:
    $ 14.27万
  • 项目类别:
Aptamers as Proteomic Tools for Pancreatic Cancer Biomarker Identification
适体作为胰腺癌生物标志物鉴定的蛋白质组学工具
  • 批准号:
    8950503
  • 财政年份:
    2015
  • 资助金额:
    $ 14.27万
  • 项目类别:
RNA Therapeutics for Pancreatic Cancer
胰腺癌的 RNA 治疗
  • 批准号:
    8699157
  • 财政年份:
    2011
  • 资助金额:
    $ 14.27万
  • 项目类别:
RNA Therapeutics for Pancreatic Cancer
胰腺癌的 RNA 治疗
  • 批准号:
    8321494
  • 财政年份:
    2011
  • 资助金额:
    $ 14.27万
  • 项目类别:
RNA Therapeutics for Pancreatic Cancer
胰腺癌的 RNA 治疗
  • 批准号:
    8531680
  • 财政年份:
    2011
  • 资助金额:
    $ 14.27万
  • 项目类别:
RNA Therapeutics for Pancreatic Cancer
胰腺癌的 RNA 治疗
  • 批准号:
    8045648
  • 财政年份:
    2011
  • 资助金额:
    $ 14.27万
  • 项目类别:

相似海外基金

ホウ素中性子捕捉療法におけるabscopal effect機序の初期探索研究
硼中子俘获治疗远隔效应机制的初步探索性研究
  • 批准号:
    24K18767
  • 财政年份:
    2024
  • 资助金额:
    $ 14.27万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Abscopal effect of 131I-MIBG therapy for refractory neuroblastoma
131I-MIBG 治疗难治性神经母细胞瘤的远隔效应
  • 批准号:
    20K22836
  • 财政年份:
    2020
  • 资助金额:
    $ 14.27万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Local oncolytic adenovirotherapy inducing the direct abscopal effect via exosome
局部溶瘤腺病毒疗法通过外泌体诱导直接远隔效应
  • 批准号:
    20K17617
  • 财政年份:
    2020
  • 资助金额:
    $ 14.27万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of a mechanism of abscopal effect -Innovative cancer treatment strategy-
阐明远隔效应的机制-创新的癌症治疗策略-
  • 批准号:
    18H02696
  • 财政年份:
    2018
  • 资助金额:
    $ 14.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Elucidation for epigenetic mechanism of Abscopal effect in rectal cancer after CRT
阐明直肠癌 CRT 后远隔效应的表观遗传机制
  • 批准号:
    18K16279
  • 财政年份:
    2018
  • 资助金额:
    $ 14.27万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The abscopal effect of nanosecond electric pulse tumor ablation and its enhancement for metastatic breast cancer
纳秒电脉冲肿瘤消融及其强化治疗转移性乳腺癌的远隔效应
  • 批准号:
    9756343
  • 财政年份:
    2018
  • 资助金额:
    $ 14.27万
  • 项目类别:
Consideration of effectiveness of intra-abdominal hyperthermia chemotherapy devised from abscopal effect
从远隔效应角度探讨腹腔热化疗的有效性
  • 批准号:
    18K08592
  • 财政年份:
    2018
  • 资助金额:
    $ 14.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a new cancer treatment method using semiconductor lasers and investigation of the abscopal effect
使用半导体激光器开发新的癌症治疗方法并研究远隔效应
  • 批准号:
    18K17222
  • 财政年份:
    2018
  • 资助金额:
    $ 14.27万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
CT detection of primary and metastatic tumor and their treatment abscopal effect via radiation
原发性和转移性肿瘤的CT检测及其放射治疗远隔效应
  • 批准号:
    17K10489
  • 财政年份:
    2017
  • 资助金额:
    $ 14.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Exploratory Optimization of Organs for Radiotherapy or Cancer Vaccination by Abscopal Effect
通过远隔效应探索性优化放疗或癌症疫苗接种的器官
  • 批准号:
    17K10473
  • 财政年份:
    2017
  • 资助金额:
    $ 14.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了